Current immunoassays and detection of antibodies elicited by Omicron SARS‐CoV‐2 infection

alexandrossfakianakis shared this article with you from Inoreader Current immunoassays and detection of antibodies elicited by Omicron SARS‐CoV‐2 infection via Journal of Medical Virology Abstract Objectives To determine whether current commercial immunoassays are adequate for detecting anti-Omicron antibodies. Methods We analyzed the anti-SARS-CoV-2 antibody response of 23 unvaccinated individuals 1-2 months after an Omicron infection. All blood samples were tested with a live virus neutralization assay using a clinical Omicron BA.1 strain and 4 commercial SARS-CoV-2 immunoassays. We assessed three anti-Spike immunoassays (SARS-CoV-2 IgG II Quant (Abbott S), Wantaï anti-SARS-CoV-2 antibody ELISA (Wantaï), Elecsys Anti-SARS-CoV-2 S assay (Roche)) and one anti-Nucleocapsid immunoassay (Abbott SARS-CoV-2 IgG assay (Abbott N)). Results Omicron neutralizing antibodies were detected in all samples with the live virus neutralization assay. The detection rate of the Abbott S, Wantai, Roche and Abbott N immunoassays were 65.2%, 69.6%, 86.9% and 91.3%, respectively. The sensitivities of Abbott S and Wantai immunoassays were significantly lower t han that of the live virus neutralization assay (p=0.004, p=0.009; Fisher's exact test). Antibody concentrations obtained with anti-S immunoassays were correlated with Omicron neutralizing antibody concentrations. Conclusion These data provide clinical evidence of the loss of performance of some commercial immunoassays to detect antibodies elicited by Omicron infections. It highlights the need to optimize these assays by adapting antigens to the circulating SARS-CoV-2 strains. This article is protected by copyright. All rights reserved. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.